KPRX
Income statement / Annual
Last year (2023), Kiora Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Kiora Pharmaceuticals, Inc.'s net income was -$12.51 M.
See Kiora Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$12,059.00
|
$2.69 M
|
$1.65 M
|
$407,518.00
|
$669,259.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.03 M |
$134,028.00 |
$227,273.00 |
$200,221.00 |
$4,889.36 |
$8.06 M |
$10.33 M |
$8.42 M |
$1,257.00 |
$0.00 |
| Gross Profit |
-$4.03 M |
-$134,028.00 |
-$227,273.00 |
-$188,162.00 |
$2.68 M |
-$6.40 M |
-$9.92 M |
-$7.75 M |
-$1,257.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
-15.6 |
1 |
-3.87 |
-24.35 |
-11.58 |
0 |
0 |
| Research and Development
Expenses |
$5.93 M
|
$3.45 M
|
$5.35 M
|
$3.57 M
|
$5.39 M
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
$2.72 M
|
$531,116.00
|
| General & Administrative
Expenses |
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
| Selling & Marketing
Expenses |
-$62,424.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
| Other Expenses |
-$2.03 M |
$582,605.00 |
$6.27 M |
$0.00 |
$0.00 |
$0.00 |
$4.64 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$8.56 M |
$11.73 M |
$10.67 M |
$8.22 M |
$9.80 M |
$12.50 M |
$14.97 M |
$14.02 M |
$6.68 M |
$2.46 M |
| Cost And Expenses |
$12.59 M |
$11.73 M |
$10.67 M |
$8.22 M |
$9.80 M |
$12.50 M |
$14.97 M |
$14.02 M |
$6.68 M |
$2.46 M |
| Interest Income |
$173,989.00 |
$56,891.00 |
$1,141.00 |
$23,339.00 |
$108,066.00 |
$120,363.00 |
$564.00 |
$3,684.00 |
$947.00 |
$1,102.00 |
| Interest Expense |
$11,132.00 |
$8,599.00 |
$6,851.00 |
$4,186.00 |
$325.00 |
$1,040.00 |
$1,215.00 |
$275.00 |
$1.93 M |
$441,720.00 |
| Depreciation &
Amortization |
$51,798.00
|
$134,028.00
|
$227,273.00
|
$200,221.00
|
$213,933.00
|
$38,483.00
|
$19,288.00
|
$5,185.00
|
$1,257.00
|
$1,724.00
|
| EBITDA |
-$8.64 M
|
-$11.63 M
|
-$10.63 M
|
-$8.16 M
|
-$6.79 M
|
-$10.69 M
|
-$14.54 M
|
-$13.34 M
|
-$6.68 M
|
-$2.46 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-676.34 |
-2.53 |
-6.47 |
-35.68 |
-19.93 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
-679.11
|
-2.61
|
-6.56
|
-35.73
|
-19.94
|
0
|
0
|
| Total Other
Income/Expenses Net |
$163,319.00
|
-$1.39 M
|
$242,761.00
|
$109,531.00
|
-$325.00
|
$119,323.00
|
-$651.00
|
$3,409.00
|
$223,182.00
|
$1.35 M
|
| Income Before Tax |
-$12.42 M |
-$13.70 M |
-$16.70 M |
-$8.08 M |
-$7.00 M |
-$10.73 M |
-$14.56 M |
-$13.34 M |
-$8.39 M |
-$1.55 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-670.03
|
-2.61
|
-6.49
|
-35.73
|
-19.94
|
0
|
0
|
| Income Tax Expense |
$90,319.00 |
-$113,010.00 |
-$304,781.00 |
$12,055.00 |
$95,396.00 |
$86,045.00 |
-$1.34 M |
$3,684.00 |
$1.94 M |
$664,204.00 |
| Net Income |
-$12.51 M |
-$13.58 M |
-$16.39 M |
-$8.09 M |
-$7.10 M |
-$10.81 M |
-$13.22 M |
-$13.34 M |
-$8.39 M |
-$1.77 M |
| Net Income Ratio |
0 |
0 |
0 |
-671.03 |
-2.64 |
-6.54 |
-32.44 |
-19.94 |
0 |
0 |
| EPS |
-24.25 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
-817.01 |
-153.35 |
| EPS Diluted |
-23.26 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
-817.01 |
-153.35 |
| Weighted Average Shares
Out |
$516,107.00
|
$732,303.00
|
$241,099.00
|
$114,787.00
|
$79,525.00
|
$59,139.00
|
$23,766.00
|
$14,723.00
|
$10,273.00
|
$11,568.00
|
| Weighted Average Shares
Out Diluted |
$538,007.00
|
$732,303.00
|
$241,099.00
|
$114,787.00
|
$79,525.00
|
$59,139.00
|
$23,766.00
|
$14,723.00
|
$10,273.00
|
$11,568.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
